Galectin-3: A Novel Marker for the Prediction of Stroke Incidence and Clinical Prognosis

Ahmed Sayed, Malak Munir, Mohamed S. Attia, Badrah S. Alghamdi, Ghulam Md Ashraf*, Eshak I. Bahbah, Mohamed Elfil

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)

Abstract

Stroke, whether ischemic or haemorrhagic, is one of the main causes of mortality and disability all over the world, which entails huge burdens in both healthcare environments as well as social and economic aspects of life. Therefore, there is a continuous search for novel reliable biomarkers that can enhance the recognition of stroke events in a timely manner and predict the clinical outcomes following a stroke event. Galectins are a group of proteins expressed by many types of cells and tissues including vasculature, certain immune cells, fibroblasts, and gastrointestinal epithelial cells. These proteins vary in their structure and configuration according to their type and have a diversity of functions according to the type of tissue they are expressed in. Among these proteins, a few studies investigated mainly the roles played by galectin-1 (Gal-1) and galectin-3 (Gal-3) in the molecular mechanisms of atherosclerosis and in brain tissue remodeling after a stroke event. In this review, we present an updated overview of the current understanding of Gal-3's functions and implications in stroke occurrence and the response of the brain tissue to stroke events, which may be a key to its utility as a predictor of stroke incidence and clinical prognosis in the future.

Original languageEnglish
Article number2924773
JournalMediators of Inflammation
Volume2022
DOIs
Publication statusPublished - 2022
Externally publishedYes

Fingerprint

Dive into the research topics of 'Galectin-3: A Novel Marker for the Prediction of Stroke Incidence and Clinical Prognosis'. Together they form a unique fingerprint.

Cite this